Cereblon Ligand-Linker Conjugates 9
98%
- Product Code: 108121
CAS:
1818885-63-0
| Molecular Weight: | 540.57 g./mol | Molecular Formula: | C₂₇H₃₂N₄O₃ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C, airtight, dry |
Product Description:
Cereblon Ligand-Linker Conjugates 9 are primarily utilized in the field of targeted protein degradation, particularly in the development of Proteolysis-Targeting Chimeras (PROTACs). These conjugates play a crucial role in designing molecules that can selectively degrade disease-causing proteins, offering a novel approach in drug discovery. By binding to the cereblon protein, they facilitate the recruitment of specific target proteins to the ubiquitin-proteasome system, leading to their degradation. This mechanism is especially promising in cancer therapy, where it can be used to degrade oncogenic proteins that are otherwise difficult to target with traditional small-molecule inhibitors. Additionally, these conjugates are being explored in the treatment of neurodegenerative diseases and other conditions driven by aberrant protein accumulation. Their ability to induce targeted protein degradation opens new avenues for therapeutic interventions, potentially overcoming limitations associated with conventional drug modalities.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.010 | 10-20 days | ฿14,328.00 |
+
-
|
Cereblon Ligand-Linker Conjugates 9
Cereblon Ligand-Linker Conjugates 9 are primarily utilized in the field of targeted protein degradation, particularly in the development of Proteolysis-Targeting Chimeras (PROTACs). These conjugates play a crucial role in designing molecules that can selectively degrade disease-causing proteins, offering a novel approach in drug discovery. By binding to the cereblon protein, they facilitate the recruitment of specific target proteins to the ubiquitin-proteasome system, leading to their degradation. This mechanism is especially promising in cancer therapy, where it can be used to degrade oncogenic proteins that are otherwise difficult to target with traditional small-molecule inhibitors. Additionally, these conjugates are being explored in the treatment of neurodegenerative diseases and other conditions driven by aberrant protein accumulation. Their ability to induce targeted protein degradation opens new avenues for therapeutic interventions, potentially overcoming limitations associated with conventional drug modalities.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :